1	Digital Health Technologies for Metabolic Disorders in
2	Older Adults: A Scoping Review Protocol
3	
4	Panitda Huynh ¹ , Elgar Fleisch ^{2,4} , Michael Brändle ³ , Tobias Kowatsch ^{*1,4,5} , Mia Jovanova ^{*1}
5	*= shared last authorship
6	
7	ORCID:
8	Panitda Huynh (0000-0002-1169-2271)
9	Elgar Fleisch (0000-0002-4842-1117)
10	Michael Brändle (0000-0002-3228-0313)
11	Tobias Kowatsch (0000-0001-5939-4145)
12	Mia Jovanova (0000-0003-3634-4449)
13	
14	Affiliations:
15	¹ School of Medicine, University of St. Gallen, St. Gallen, Switzerland
16	² Institute of Technology Management, University of St.Gallen, St. Gallen, Switzerland
17	³ Internal Medicine & Endocrinology/Diabetes, Kantonsspital St. Gallen, St.Gallen, Switzerland
18	⁴ Centre for Digital Health Interventions, Department of Management, Technology and
19	Economics, ETH Zürich, Zurich, Switzerland
20	⁵ Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland
21	
22	**corresponding author: mia.jovanova@unisg.ch
23	Keywords: aging; older adults; digital health technologies; metabolic disorders; elderly care;
24	burden; healthy aging
25	
26	Abstract
27	Introduction: Metabolic disorders (type 2 diabetes, insulin resistance, hyperglycemia, obesity,
28	hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and metabolic syndrome) are lead-
29	ing causes of mortality and disability worldwide and disproportionately affect older adults rela-
30	tive to those younger. Digital health technologies (DHTs), such as patient monitoring, digital
31	diagnostics, and digital therapeutics, emerge as promising tools for navigating health in day-to- 1

32	day life. However, their role in targeting metabolic disorders, particularly among a key demo-
33	graphic of older adults, is not yet fully understood. Thus, this work aims to scope the use of
34	DHTs in managing metabolic health disorders among older adults.
35	Methods and Analysis: We will conduct a scoping review following the recommended frame-
36	work by Arksey and O'Malley (1). Our search will focus on three primary concepts: metabolic
37	disorders, DHTs, and older adults. We plan to search five online databases-Cochrane, Embase,
38	PubMed, Scopus, and Web of Science-to identify original research articles published between
39	January 2014 and January 2024. Two reviewers will independently screen articles for inclusion
40	based on predetermined criteria, and a separate reviewer will resolve conflicts. Data will be ex-
41	tracted using a standardized form, and the findings will be synthesized and reported qualitatively
42	and quantitatively.
43	Ethics and dissemination. No ethics approval is required for this protocol and scoping review,
44	as data will be used only from published studies with appropriate ethics approval. Results will be
45	disseminated in a peer-reviewed publication.
46	
47	This protocol has been preregistered on OSF Repository at: https://osf.io/9s8fm.
48	
49	Strengths and limitations of this study
50	• To our knowledge, this scoping review is the first to scope the landscape of DHTs for tar-
51	geting metabolic disorders among older adults.
52	• We apply the DHT Ecosystem Categorization for a more standardized overview of the
53	peer-reviewed empirical literature across multiple databases and follow rigorous scoping
54	review reporting guidelines.
55	• Consistent with the nature of scoping reviews, our study does not include an assessment
56	of the quality of the included studies, only involves studies in English, and does not in-
57	clude non-peer reviewed industry reports, which may also provide relevant information.
58	• Since our pre-existing definition of metabolic disorders focuses on various pre-defined
59	major conditions, there exists a possibility that we may not comprehensively capture all
60	possible instances of metabolic disorders among older adults.
61	

62 **1 BACKGROUND**

63 Non-communicable diseases (NCDs) are primary drivers of morbidity and mortality globally, 64 with estimates by the World Health Organization (WHO) to surpass 15 million premature deaths attributed to NCDs per year (2). Over 50% of cases of NCDs is attributed to a growing preva-65 66 lence of metabolic disorders; namely type 2 diabetes mellitus (T2DM), hypertension (HTN), hy-67 perlipidaemia (HLD), obesity and more recently, non-alcoholic fatty liver disease (NAFLD) 68 (2,3). Metabolic disorders are more prevalent among older adults versus younger populations, in 69 part due to age-related physiological changes in metabolism and hormones, cumulative effects of 70 lifestyle factors (e.g., nutrition, sleep, and physical activity), and susceptibility to related comor-71 bidities (e.g. cardiovascular diseases, diabetes) (4-6). Metabolic disorders are often defined as 72 conditions that affect the body's conversion of food into energy and the ability to eliminate waste 73 (7). Key factors contributing to the risk of metabolic disorders are the intake of an unhealthy diet, 74 a sedentary lifestyle, and insufficient exercise, among others (7). Nonpharmaceutical intervention efforts that target lifestyle factors are a promising approach to 75 76 navigating metabolic disorders (7), and increasingly involve digital health technologies (DHTs)-77 which are defined by the Food and Drug Administration (FDA) as "computing platforms, con-78 nectivity, software, and sensors used for health care and related uses (8,9). Notably, DHTs may 79 help older adults and caregivers manage aspects of metabolic health in day-to-day life (vs. in the 80 clinic) and overcome barriers of more traditional health assessments (10), e.g., by reducing costs 81 associated with in-person visits for patients and reducing burden for healthcare professionals, 82 enhanced experience for patients, as well as improved mental health for healthcare professionals 83 (11). However, DHTs are rapidly evolving and are often studied under inconsistent terminologies 84 (10,12,13). This heterogeneity complicates efforts to synthesize evidence on their prevalence and 85 potential impact in metabolic and related health contexts (13,14). 86 In response, the international organization overviewing DHT implementation in healthcare, the 87 Digital Therapeutics (DTx) Alliance, has called for systematic overviews of DHTs and a shared 88 language to facilitate standardization (8,9). To this end, DTx Alliance has formally categorized

89 DHTs according to their intended purpose in five categories (see Table 1): (i) promoting health &

90 wellness, (ii) patient monitoring, (iii) care support, (iv) digital diagnostics, and (v) digital thera-

91 peutics (15). These classification guidelines aim to help map a wide range of existing products by

92 their intended use and offer a more consistent and actionable language for different stakeholders,

93 including researchers, medical professionals, patients, and policymakers (8).

94 In line with recent calls for systematic synthesis of DHTs in healthcare (13,16–18), several scop-95 ing reviews have recently overviewed the role of digital health applications in navigating NCDs 96 (14,19–21), health promotion (22), and their associated barriers and facilitators (19–21) among 97 older adults. In parallel, a separate line of work has begun to review the scope of interventions in 98 promoting behaviors related to metabolic health, such as physical activity and nutrition among 99 older adults (5,23). However, this work has not yet considered specific the role of DHTs in the 100 context of metabolic health. Bridging these disparate lines of work, we aim to scope DHTs in 101 metabolic disorders among older adults, encompassing a twofold objective. First, following 102 guidelines from the DTx Alliance, we overview the prevalence of DHTs, and different DHT sub-103 categories, in navigating metabolic disorders in older adults. Second, we seek to identify how are 104 DHTs used to address metabolic disorders among older adults and by whom. To our knowledge, 105 this review will be the first to provide an overview of the DHT landscape in metabolic disorders 106 among older adults.

107

DHT Cate-	Health & Patient		Care Sup-	Digital Di-	Digital	
gory	Wellness	Monitoring	port	agnostics	Therapeutics	
Definition	Disease-agnostic	Digital solu-	Digital solu-	Validated digi-	Health soft-	
	digital health	tions intended	tions intended	tal tools and	ware intended	
	solutions	to monitor	to	software that	to treat or alle-	
	that primarily	specific health	help patients	deliver a	viate a specific	
	capture	data, which	better manage	diagnosis or	disease or	
	and store general	may be	their care of a	prognosis of	medical condi-	
	health data and	interpreted by	specific dis-	a specific dis-	tion by gener-	
	promote healthy	physician	ease or medi-	ease or medi-	ating and de-	
	living	for clinical	cal condition	cal condition	livering a	
		management			medical	
					intervention	
Claims	No claims to	May make	May make	Make a clini-	Make a clini-	
	treat,	non-clinical	non-clinical	cal claim to	cal claim to	
	improve, or	claims to	claims to	diagnose or	treat or alle-	
	diagnose a	assess patient	improving	assess a	viate a spe-	

108 Table 1: Digital Health Technology Ecosystem Categorization

medical condi-	data	health adja-	specific dis-	cific disease
tion		cent meas-	ease or medi-	or medical
		ures (e.g.,	cal condition	condition
		adherence)		

109 Note: The Digital Health Technology Ecosystem Categorization is adapted from DTx Alliance

and provides a uniform overview of different DHT categories by their intended use. (8)

111 2 METHODS AND ANALYSIS

- 112 For this review, we will adopt the framework outlined by Arksey and O'Malley (1), which in-
- 113 volves a five-stage process: (i) formulating the research question, (ii) locating relevant studies,
- 114 (iii) choosing studies that meet our criteria, (iv) extracting and organizing data, and (v) compiling
- and synthesizing findings. Additionally, we will adhere to the Preferred Reporting Items for Sys-
- 116 tematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) (24).

117 2.1 Identifying Research Questions

118 Following Arksey and O'Malley's framework (1), we implemented an iterative process to define

119 our research questions. We identified gaps in previous scoping reviews (14,19,20), conducted

120 literature searchers, and engaged in discussions with industry and healthcare professionals fo-

- 121 cused on promoting metabolic health among older adults. We pose the following questions:
- 122

123 RQ1. How prevalent are DHTs in targeting metabolic disorders in older adults?

- 124 RQ2. What specific classes of DHTs have been implemented to address metabolic disorders in125 older adults?
- 126 RQ3. By whom are DHTs used in metabolic disorders contexts?
- 127
- 128 The formulation of these research questions was guided by the PIO (Population, Intervention,

129 Outcome) concept, as detailed in Table 2, drawing on methodologies from previous studies

130 (22,25).

131 *Table 2: The PIO framework for the eligibility of studies*

Concept	Determinants
P – Population	Older people (65 or above)
I – Intervention	Digital Health Technologies

O – Outcome	Metabolic Disorders
-------------	---------------------

132

133 2.2 Identifying relevant studies

134 The methodology for searching literature in this scoping review is outlined in Table 2, based on 135 each PIO (Population, Intervention, Outcome) concept. Initial search terms were established 136 through a preliminary review, particularly by identifying search terms adopted in prior studies on 137 DHTs, older adults and metabolic health (5,21) (See Table 3). To ensure the search was both pre-138 cise and comprehensive, all authors participated in a consensus-building process. The literature 139 search will span across five major electronic databases: Cochrane, Embase, PubMed, Scopus, and 140 Web of Science, focusing on publications from January 2014 to January 2024, to capture recent 141 advancements in technology. For each database, we will use pre-identified terms on DHTS, met-142 abolic health, and older adults (See Table 3) to search titles, abstracts, and, when available, Med-143 ical Subject Headings (MeSH) terms, or else keywords. Within each PIO concept, the Boolean 144 operator 'OR' will be used to combine search terms, and then the different concepts will be con-145 nected using the 'AND' operator.

146

Concept	Search Terms
1: Older people (65 or above) (21)	(Older adult* OR Older person OR Elderly
	OR 65 or above)
2: DHTs (21)	(Internet OR Telemonitor* OR Teleconsultat*
	OR
	Telehealth OR Telecare OR Website* OR
	Apps* OR Application* OR Digital OR
	eHealth* OR
	mHealth* OR Health and Wellness* OR Pa-
	tient Monitoring* OR Care Support* OR Dig-
	ital Diagnostics* OR Digital Therapeutics*)
3: Metabolic Disorders (5)	("metabolic health") OR metabolic syn-
	drome[MeSH Major Topic]) OR hyperglyce-
	mia[MeSH Major Topic]) OR insulin re-
	sistance[MeSH Major Topic]) OR diabetes
	mellitus, type 2[MeSH Major Topic]) OR
	obesity[MeSH Major Topic]) OR
	dyslipidemias[MeSH Major Topic]) OR hy-
	perlipidemias[MeSH Major Topic]) OR hy-
	pertriglyceridemia[MeSH Major Topic]) OR
	hypercholesterolemia[MeSH Major Topic])

147 Table 3: Search terms derived for the PIO framework

	OR hypertension[MeSH Major Topic]) OR non-alcoholic fatty liver disease[MeSH Major Topic]

148 *Note*: Search terms adapted from Michels et al. & Cheng et all. (5,21)

149 **2.3 Selection of eligible studies**

- 150 The process of reviewing titles and abstracts will adhere to the PIO framework (outlined in Table
- 151 2), using the inclusion and exclusion selection criteria detailed in Table 4 to guarantee that the
- 152 studies included directly follow our a-priori defined research questions.
- 153

154 Table 4: Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
 Articles published between January 2014 and January 2024 Original or review research articles Qualitative (qualitative descriptive, phenomenological, ethnographical, grounded theory, realistic evaluation, action research, and so on), quantitative (random controlled trials, cohort study, case–control and cross-sectional, and so on) or reviews (systematic review, meta-analysis, scoping review) Articles with a primary focus on DHTs for metabolic health Articles with a primary focus on DHTs for older adults Older individuals 65 years of age or older (or where the average age of the study sample was 65 years of age or older) who had any metabolic disorders (such as insulin resistance, hyperglycemia, type 2 diabetes, obesity, hyperlipidemia, hypertension, non-alco-holic fatty liver disease (NAFLD), and metabolic syndrome) 	 Articles not in English Articles that do not primarily focus on metabolic syndrome in older adults (aged 65 and above). Articles which discuss metabolic disorders negligibly or with other comorbidities/health conditions Articles that mention DHTs briefly or as an insignificant part Book chapters, commentaries, conference proceedings, editorials, interviews, opinion pieces, proposals, reports, short news, study protocols) Non-human studies

155

156 **2.4 Charting the data**

- 157 A form for extracting data will be employed to collect relevant information from every selected
- 158 article (See Table 5). The process of charting this data will be conducted by hand.
- 159 Table 5: Data Charting Form adapted from Schneider et al. (2023) (22)

Title of study	
DOI	
Year of publication	
Author name/s	
Author location/s	
Study approach	i.e., qualitative or quantitative or mixed method
Type of article	i.e., Case Study, Observational Study, RCT, Review, Trial, Other
Study location	i.e., where the study was carried out
DHT Category as	i.e., Digital Therapeutics, Digital Diagnostics, Care Support, Patient
defined by DTx Al-	Monitoring, Health and Wellness
liance	
DHT Use whom	i.e., by who is DHT used (e.g., healthcare provid- er/researcher/patient)
Outcome measured	i.e., the primary outcome being measured in the study
Notes	

160

161 **2.5 Collating, summarizing, and reporting results**

162 After completing full-text reviews guided by the data extraction charts, we will synthesize the 163 extracted data in descriptive frequency tables. In line with our three research questions, we will 164 first describe the overall frequency of DHTs in studies targeting metabolic disorders in older 165 adults. We will first conduct a comprehensive review of relevant literature and report the preva-166 lence of DHTs across the studies included in our sample (RQ1). Second, we will describe the 167 frequency of each DHT category (promoting health & wellness, (ii) patient monitoring, (iii) care 168 support, (iv) digital diagnostics, and (v) digital therapeutics (15) in targeting metabolic disorders 169 among older adults (RQ2). Next, we will describe by whom are DHTs used across all the six 170 DHTs categories. By categorizing the different types of DHTs, we aim to provide a comprehen-171 sive understanding of their utilization in addressing metabolic disorders among older adults and 172 summarize the current DHTs landscape in targeting metabolic disorders.

173 **2.6 Ethics and dissemination**

The current review will compile information from existing literature and thus does not require additional ethical clearance. Findings from the scoping review will offer potential relevant insights to researchers, policymakers, and healthcare practitioners about the degree to which DHTs are used to target metabolic health orders in older adults and through what relevant approaches, i.e., via health & wellness, patient monitoring, care support, digital diagnostics, and digital thera-

peutics. The findings will be shared via a scholarly article in a peer-reviewed journal and pre-sented at academic conferences.

181 **3 DISCUSSION & CONCLUSION**

182 Overall, the proposed scoping review aims to synthesize the prevalence of DHTs and provide 183 insight into DHTs are used to diagnose, manage, and possibly prevent metabolic disorders in old-184 er adults. This scoping review will contribute to a growing body of literature on DHTs in 185 healthcare by specifically focusing on a key demographic of older adults in metabolic disorder 186 contexts. Compared with prior review articles, this study stands out as the first, to our knowledge, 187 to systematically categorize DHTs specifically for older adults, with a concentrated focus on 188 metabolic disorders. To this end, the scoping review presents an important step in standardizing 189 the literature by adopting the DTx Alliance classification framework (8,9). By adopting the DTx 190 Alliance classification framework, we aim to help standardize terminology and categorization 191 within the literature, thereby potentially improving consistency and comparability across studies.

192 The scoping review presents several significant limitations. As this study encompasses articles 193 featuring a variety of study designs and does not evaluate their quality, it is not designed to re-194 solve questions regarding specific recommendations of DHTs for managing metabolic disorders 195 in older adults. Additionally, the scope of this review is restricted; articles not written in English 196 or lacking a full-text version will be excluded. We also exclude non-peer-reviewed industry 197 sources, which may overlook cutting-edge developments that have not yet been incorporated into 198 the academic literature. Upon completing the full-text review, we intend to comprehensively pre-199 sent both the strengths and limitations of our findings. Furthermore, any deviations from the ini-200 tial protocol will be transparently reported in the final scoping review.

Overall, our efforts to synthesize the prevalence and use of DHTs in managing metabolic disorders among older adults ae expected to highlight essential areas where DHTs are present versus lacking in the existing literature. Specifically, our findings could reveal key areas where DHTs are underutilized among older adults in metabolic health contexts, thus presenting opportunities for increased DHT inclusion and enhancement. Our results may also offer insights into strategic areas for expanding the use of DHTs for older adults. Together, this review will help better understand the DHTs landscape to tackle metabolic health in the older population.

208 **4 REFERENCES**

- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005 Feb 1;8(1):19–32.
- Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018
 Feb 26;20(2):12.
- Chong B, Kong G, Shankar K, Chew HSJ, Lin C, Goh R, et al. The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the
 Global Burden of Disease 2000–2019. Metabolism. 2023 Apr 1;141:155402.
- Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep. 2010 Apr;12(2):113–9.
- 5. Michels N, Zouiouich S, Vanderbauwhede B, Vanacker J, Indave Ruiz BI, Huybrechts I.
 Human microbiome and metabolic health: An overview of systematic reviews. Obesity Reviews. 2022;23(4):e13409.
- 6. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome.
 Clin Dermatol. 2018;36(1):14–20.
- 7. Mishra S, Raval M, Kachhawaha AS, Tiwari BS, Tiwari AK. Chapter Eight Aging: Epigenetic modifications. In: Singh V, Mani I, editors. Progress in Molecular Biology and Translational Science [Internet]. Academic Press; 2023 [cited 2024 Jan 16]. p. 171–209. (Epigenetics in Health and Disease - Part A; vol. 197). Available from:
- 227 https://www.sciencedirect.com/science/article/pii/S1877117323000364
- 8. Digital Therapeutics Alliance [Internet]. [cited 2023 Dec 21]. DTx Evaluation Toolkit. Avail able from: https://dtxalliance.org/understanding-dtx/dtx-evaluation-toolkit/
- 9. Health C for D and R. What is Digital Health? FDA [Internet]. 2020 Sep 22 [cited 2023 Dec
 21]; Available from: https://www.fda.gov/medical-devices/digital-health-centerexcellence/what-digital-health
- 10. Bhattarai P, Phillips JL. The role of digital health technologies in management of pain in older people: An integrative review. Archives of Gerontology and Geriatrics. 2017 Jan 1;68:14–
 24.
- 11. Singh S, Bajorek. B. Defining 'elderly' in clinical practice guidelines for pharmacotherapy.
 Pharm Pract (Granada). 2014;12(4):489.
- 12. Kunonga TP, Spiers GF, Beyer FR, Hanratty B, Boulton E, Hall A, et al. Effects of Digital
 Technologies on Older People's Access to Health and Social Care: Umbrella Review. Journal
 of Medical Internet Research. 2021 Nov 24;23(11):e25887.
- 13. Oh SS, Kim KA, Kim M, Oh J, Chu SH, Choi J. Measurement of Digital Literacy Among
 Older Adults: Systematic Review. J Med Internet Res. 2021 Feb 3;23(2):e26145.

- 14. Matthew-Maich N, Harris L, Ploeg J, Markle-Reid M, Valaitis R, Ibrahim S, et al. Designing,
 Implementing, and Evaluating Mobile Health Technologies for Managing Chronic Conditions in Older Adults: A Scoping Review. JMIR mHealth and uHealth. 2016 Jun
 9;4(2):e5127.
- 15. Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Metabolic syndrome in the elderly. Curr
 Diab Rep. 2006 Jan 1;6(1):64–71.
- 16. Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, et al. The Effectiveness of Mobile-Health Technologies to Improve Health Care Service Delivery Processes: A Systematic
 Review and Meta-Analysis. PLOS Medicine. 2013 Jan 15;10(1):e1001363.
- 17. Liu L, Stroulia E, Nikolaidis I, Miguel-Cruz A, Rios Rincon A. Smart homes and home
 health monitoring technologies for older adults: A systematic review. International Journal of
 Medical Informatics. 2016 Jul 1;91:44–59.
- 18. Alhussein G, Hadjileontiadis L. Digital Health Technologies for Long-term Self-management
 of Osteoporosis: Systematic Review and Meta-analysis. JMIR Mhealth Uhealth. 2022 Apr
 21;10(4):e32557.
- 19. De Santis KK, Mergenthal L, Christianson L, Busskamp A, Vonstein C, Zeeb H. Digital
 Technologies for Health Promotion and Disease Prevention in Older People: Scoping Review. J Med Internet Res. 2023 Mar 23;25:e43542.
- 20. Linn N, Goetzinger C, Regnaux JP, Schmitz S, Dessenne C, Fagherazzi G, et al. Digital
 Health Interventions among People Living with Frailty: A Scoping Review. Journal of the
 American Medical Directors Association. 2021 Sep 1;22(9):1802-1812.e21.
- 264 21. Cheng KKF, Siah RCJ, Ream E, Kanesvaran R, Armes J. Protocol for a scoping review of
 265 digital health for older adults with cancer and their families. BMJ Open. 2020 Aug
 266 1;10(8):e038876.
- 267 22. Schneider C, Kowatsch T, Vinay R. Impact of digital assistive technologies on the quality of
 268 life for people with dementia: protocol for a scoping review. BMJ Open. 2023 Dec
 269 13;13(12):e077017.
- 23. Taylor J, Walsh S, Kwok W, Pinheiro MB, de Oliveira JS, Hassett L, et al. A scoping review
 of physical activity interventions for older adults. International Journal of Behavioral Nutrition and Physical Activity. 2021 Jun 30;18(1):82.
- 273 24. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension
 274 for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct
 275 2;169(7):467–73.
- 25. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a
 key to evidence-based decisions. ACP J Club. 1995;123(3):A12-13.
- 278
- 279

280

281 Footnotes

282 Author Statement: All authors have made substantial intellectual contributions to the develop-283 ment of this protocol and its revisions. The search question originated with TK, MJ and PH, then 284 was expanded upon by MB and EF. The methodology and design of the review were conceived 285 by PH, guided by suggestions from TK. The development and refinement of the search terms 286 were a collaborative effort between MJ and PH, incorporating feedback and revisions from TK, 287 MB and EF. The final version of the manuscript received unanimous approval from all authors. 288 Conflicts of interests: TK and MJ are affiliated with the Centre for Digital Health Interventions, 289 a joint initiative of the Institute for Implementation Science in Health Care, University of Zurich, 290 the Department of Management, Technology, and Economics at ETH Zurich, and the Institute of 291 Technology Management and School of Medicine at the University of St.Gallen, Centre for Digi-292 tal Health Interventions is funded in part by MavieNext, an Austrian health care provider, CSS, a 293 Swiss health insurer, and MTIP, a growth equity firm. TK is also a co-founder of Pathmate Tech-294 nologies, a university spin-off company that creates and delivers digital clinical pathways. How-295 ever, neither CSS, MTIP, nor Pathmate Technologies was involved in this protocol. All other 296 authors have no conflicting interests.

Funding: This research received no specific grant from any funding agency in the public, com-mercial or not-for-profit sectors.

299 **Patient consent:** Not required.

300 **Provenance and peer revie**w: Not commissioned; externally peer reviewed.